WO2002080774A2 - Method for improved measurement of local physical parameters in afluid-filled cavity - Google Patents
Method for improved measurement of local physical parameters in afluid-filled cavity Download PDFInfo
- Publication number
- WO2002080774A2 WO2002080774A2 PCT/IB2002/001229 IB0201229W WO02080774A2 WO 2002080774 A2 WO2002080774 A2 WO 2002080774A2 IB 0201229 W IB0201229 W IB 0201229W WO 02080774 A2 WO02080774 A2 WO 02080774A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ultrasound
- gas
- gas bubbles
- measuring method
- pulsed
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
- G01N29/02—Analysing fluids
- G01N29/036—Analysing fluids by measuring frequency or resonance of acoustic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01L—MEASURING FORCE, STRESS, TORQUE, WORK, MECHANICAL POWER, MECHANICAL EFFICIENCY, OR FLUID PRESSURE
- G01L11/00—Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by means not provided for in group G01L7/00 or G01L9/00
- G01L11/04—Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by means not provided for in group G01L7/00 or G01L9/00 by acoustic means
- G01L11/06—Ultrasonic means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/02—Investigating particle size or size distribution
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N2015/0007—Investigating dispersion of gas
- G01N2015/0011—Investigating dispersion of gas in liquids, e.g. bubbles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/024—Mixtures
- G01N2291/02433—Gases in liquids, e.g. bubbles, foams
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/028—Material parameters
- G01N2291/02854—Length, thickness
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/028—Material parameters
- G01N2291/02872—Pressure
Definitions
- the present invention relates to a noninvasive measuring method for remotely determining local physical parameters of a fluid- filled cavity, by means of ultrasound waves and encapsulated or stabilized gas bubbles (e.g. suspensions of stabilized microbubbles, microballoons or micropar tides comprising gas).
- encapsulated or stabilized gas bubbles e.g. suspensions of stabilized microbubbles, microballoons or micropar tides comprising gas.
- Physiological parameters of the cardiovascular system are important since they provide essential information concerning the state of health of organs and the patient.
- dynamic blood pressure measurements are mainly performed by catheterization, consisting of a pressure-sensing catheter that is inserted into the heart chamber or blood vessel, or by Doppler echocardiography using the simplified Bernoulli equation (Burton C. Physiology and biophysics of the circulation. 2 nd edition. Chicago, 1972).
- the first method is accompanied by the disadvantages of an invasive procedure, i.e. creating pain and risk of infection.
- the second, noninvasive method does not provide reliable or reproducible blood pressure values (Strauss AL, Roth FJ, Rieger H. "Noninvasive assessment of pressure gradients across iliac artery stenoses: duplex and catheter correlative study" J Ultras Med 1993; 12: 17-22).
- the size of a gas bubble changes as a function of the local hydrostatic pressure. This change in size affects the acoustic characteristics of the gas bubble, like resonance frequency, scattering and attenuation cross-section, etc. Therefore, the local pressure in a fluid-filled cavity can be derived from these acoustic characteristics.
- this method strongly depends on the size of the bubbles at the location where the pressure is to be measured.
- the size distribution will change due to lung filtration and microbubble uptake. Therefore, the exact size of the bubbles, and consequently the acoustic characteristics like sub- and ultraharmonic response, at the location of interest is unknown. It is an object of the present invention to provide a new method for accurate and sensitive, noninvasive measurement of the local physical parameters in a fluid-filled cavity. With this new method small pressure changes (5- 10 mmHg) can be measured, which is the main limitation of the methods described by aforementioned references.
- the size of the bubbles at the location where the pressure is to be measured can be better controlled and, therefore, the acoustic characteristics of the bubbles at the site of interest are better specified, which makes the present invention more accurate.
- the present invention entails shorter acquisition time, which makes it more efficient and more useful in the clinic.
- This new method can provide clinicians with a valuable tool for determining the state of health of an organ without the risk of infection and with minimal patient discomfort.
- the present invention can be used as a general technique for remotely sensing physical parameters, for example in situations where direct measurement is impossible or too dangerous.
- the stabilized or encapsulated gas bubbles useful in the invention may be divided into several categories : stabilized gasmicrobubbles, gas-filled microcapsules/ microballoons, and gas containing microparticles according to the definitions given in for example, in EP 554213 and US 5,413,774.
- microbubble specifically designates gas bubbles, in suspension in a liquid preferably also containing surfactants or tensides to control the surface properties and the stability of the bubbles.
- microcapsule or “microballoon” designates preferably air or gas-filled bodies with a material boundary or envelope, i.e. a polymer membrane wall.
- microparticle refers to gas-containing solid systems, for example microparticles (especially aggregates of microparticles) having gas contained therein or otherwise associated therewith (for example being adsorbed on the surface thereof and/ or contained within voids, cavities or pores therein).
- Free-gas bubbles i.e. gas bubbles that are not stabilized by any means (gas bubbles which are neither stabilized by tensides or surfactants nor encapsulated by, for example, a polymer or contained in or associated with solids) are obtained from these stabilized or encapsulated gas bubbles by the destruction of the stabilized microbubbles, microballoons or microparticles by, for example, application of one or more ultrasound pulsed waves.
- the released free gas bubbles dissolve in the surrounding liquid. Consequently, the bubbles shrink and the sub- and/ or ultraharmonic response, which is very sensitive to bubble size, changes as a function of time.
- the time for a gas bubble to completely dissolve in the surrounding liquid is a function of local parameters like gas concentration, temperature and pressure.
- FIG. 3A Radius-time curves for a 2.2 ⁇ m air bubble in water at 0 mmHg overpressure, calculated by using equation (1).
- Figure 3B Sub- and ultraharmonic response and associated spectrum of a 2.2- ⁇ m air bubble, 25 ms after release.
- Figure 3C Sub- and ultraharmonic response and associated spectrum of a 2.2- ⁇ m air bubble, 45 ms after release.
- Figure 3D Sub- and ultraharmonic response and associated spectrum of a 2.2- ⁇ m air bubble, 60 ms after release.
- One aspect of the present invention is to provide a noninvasive measuring method for remotely determining local physical parameters of a fluid-filled cavity, based on the combined use of encapsulated or stabilized gas bubbles and ultrasound waves, said measuring method comprising the steps of: a) administering stabilized or encapsulated gas bubbles to a fluid filled cavity; b) applying with a transducer a first ultrasound pulsed wave or a train of pulsed waves to the fluid filled cavity to destroy the stabilized or encapsulated gas bubbles and generate free gas bubbles c) applying with a transducer a second ultrasound pulsed wave or train of pulsed waves at a frequency specifically chosen for exciting the sub- and/ or ultraharmonic response of the bubbles d) determining the mean response time. e) determining a value for a local physical parameter on the basis of the response time of step d)
- the local physical parameters considered here are the pressure, the temperature or the gas concentration.
- the essential features of the invention lie in that the sub- and/ or ultraharmonic responses of step b) are monitored as a function of time by successive ultrasound pulses, this function being an indication of the local physical parameter being measured.
- the method of the present invention provides improved accuracy and efficiency by measuring the sub- and ultraharmonic response as a function of time.
- the first ultrasound pulsed wave or train of pulsed waves is tuned in such a way (e.g. by adjusting its frequency and /or amplitude) that the size of the released free-gas bubbles is larger than the subharmonic size (as defined later in the specification).
- the frequency and amplitude of the first ultrasound pulsed wave or train of pulsed waves, to optimize gas release can be chosen independently of the second ultrasound pulsed wave or train of pulsed waves, used for monitoring the sub- and/ or ultraharmonic response.
- the frequency and amplitude of the second ultrasound pulsed wave or train of pulsed waves, used for monitoring the sub- and/ or ultraharmonic response can be chosen independently of the first ultrasound pulsed wave or train of pulsed waves, to optimize gas realise.
- the transducer used to apply the first ultrasound pulsed wave or train of pulsed waves can be the same as or distinct from that used for applying the second ultrasound pulsed wave or train of pulsed waves.
- the invention provides a method of diagnostic ultrasound for determining local physical parameters of a fluid-filled cavity "in situ", which comprises the steps of: a) administering to a subject a fluid agent comprising encapsulated or stabilised gas bubbles b) applying with a transducer a first ultrasound pulsed wave or a train of pulsed waves to generate free-gas bubbles c) applying with a transducer a second ultrasound pulsed wave or train of pulsed waves around a frequency specifically chosen for exciting the sub- and/ or ultraharmonic response of the bubbles d) determining the mean response time e) determining a value for a local physical parameter on the basis of the response time of step d) characterised in that the sub- and/ or ultraharmonic responses of step c) are monitored as a function of time by successive ultrasound wave pulses, this function being an indication of the physical parameter being measured.
- said subject is a vertebrate
- said fluid agent containing encapsulated or stabilised gas bubbles is introduced into the vasculature or into a body cavity of said vertebrate.
- the invention provides an apparatus for carrying out the above method of measurement.
- This apparatus comprises elements found in ultrasound equipment, coupled with a specific software to generate the required excitations and monitoring transmit-pulse sequences, plus the signal-processing functions required for interpreting the observed responses as a function of the local physical parameters.
- the apparatus includes for example: timing circuits, at least one pulse or arbitrary waveform generator with amplifier, at least one transmit-transducer capable of projecting an ultrasound wave into the region of interest, at least one receive-transducer sensitive to the reflected ultrasound waves, at least one receiving circuit dedicated to the amplification and conditioning of the echo signals, analog or digital circuits dedicated to perform filtering of the echo responses from microbubbles, a Central Processing Unit capable of performing the required computations and comparisons with look-up tables to derive values of the local physical parameters, a memory for storing the required programs, look-up tables, signal data and computed values, and display means for presenting the computed values in a graphical or textual form.
- the objective of the present invention relates to the remote measurement of local physical parameters in a fluid-filled cavity (e.g. heart cavities, blood vessels, industrial container, etc.) by means of ultrasound waves and encapsulated or stabilized gas bubbles, which are used as a vehicle for delivering free-gas bubbles to a site of interest.
- Stabilisation or encapsulation of the gas by means of, for example, stabilizing with a tenside or surfactant, encapsulating a gas bubble by a wall or shell, or associating it with a solid prevents the gas content from rapidly dissolving in the surrounding liquid.
- the stabilized or encapsulated structure is ruptured by means of ultrasound waves and the gas content is subsequently released.
- the release can be optimally tuned for releasing known-size free-gas bubbles e.g. by adjusting the frequency and/ or the amplitude of the applied ultrasound wave (Frinking et al. "Scattering properties of encapsulated gas bubbles at high ultrasound pressures" Joum. Acoust. Soc. Am. 1999: 105; 1989-1996).
- free-gas bubbles are more susceptible to changes in environmental conditions, like changes in temperature, gas concentration or local pressure, compared to stabilized or encapsulated gas bubbles.
- the time for a free-gas bubble to completely dissolve in the surrounding liquid i.e. the disappearance time, depends on the type of gas. This is reflected in equation (1) by the Ostwald coefficient and diffusion constant of a gas. For example, for a 2.2- ⁇ m gas bubble the disappearance time is 3.2 ms for CO2, 120.8 ms for air and 2936.6 ms for C4F10 ( Figure 1).
- the dissolution of micron- sized free- gas bubbles is caused by a difference in gas concentration between the gas inside the bubble and inside the liquid due to surface tension and overpressure.
- the radius-time curve for a 2.2- ⁇ m air bubble in water is simulated at values of the overpressure of 0 mmHg and 200 mmHg. It is assumed that temperature and gas concentration are constant. The disappearance time is 120.9 and 94.1 ms, respectively.
- the ultrasound parameters for releasing free gas bubbles are tuned in such a way (e.g. by adjusting its frequency and/ or amplitude) that the size of the released bubbles is larger than the subharmonic size.
- the subharmonic size of a gas bubble is defined as the radius of the bubble for which the resonance frequency equals half the transmitted frequency (fo).
- the response of the gas bubble to the monitoring ultrasound waves will show the appearance of subharmonics (l /2fo, l /3fo, 3/4fo...) of the transmitted frequency. Additionally, the response of the gas bubble to the ultrasound waves will show the appearance of ultraharmonics (3/2fo, 5/2fo...) of the transmitted frequency.
- figure 3 shows the response of a 2.2- ⁇ m air bubble to an ultrasound wave at different time instants during gas dissolution in the surrounding liquid at 0 mmHg overpressure (101.3 kPa).
- the subharmonic component is chosen to be l/2fo and the ultraharmonic component is chosen to be 3/2fo.
- Figure 3A shows the radius-time curve of a 2.2- ⁇ m air bubble in water.
- the three dots, I, II and III correspond to a bubble size greater than subharmonic size, at subharmonic size and smaller than subharmonic size, respectively.
- the corresponding time and frequency responses are shown in figures 3B, 3C and 3D for I, II and III, respectively.
- the sub- and ultraharmonic responses of gas bubbles are very sensitive to their sizes. Consequently, the sub- and ultraharmonic responses of gas bubbles are very sensitive to parameters that influence the bubble size. Measuring the change in bubble size due to gas dissolving in the surrounding liquid, by means of the response of sub- and/ or ultraharmonics as a function of time, an improved estimation of the local pressure or other parameters can be made. It should be mentioned that the improved sensitivity for noninvasive measurement in a fluid-filled cavity, as shown in this invention, is only obtainable by the combination of the sub- and /or ultraharmonic response and the disappearance time of the released gas bubbles.
- the mean sub- or ultraharmonic response time is defined as the mean time (weighted by for example the energy or correlation coefficient of the sub- or ultraharmonic response) for sub- or ultraharmonics to appear after the release of the gas from the stabilized or encapsulated gas bubble.
- absolute values of the local physical parameters can be derived from the mean response time, as calculated in equation 2, by comparing the calculated mean response time with predetermined values listed in calibration or lookup tables.
- the sub- and/ or ultraharmonic component of the transmit frequency can be obtained by standard signal processing techniques, like digital band-pass filtering of the time responses.
- the energy of the sub- and/ or ultraharmonic components of the transmit frequency as a function of time is obtained by taking the sum of the squared value of the filtered responses at each time point.
- the correlation of the sub- and/or ultraharmonic components of the transmit frequency as a function of time is obtained by taking the correlation between the filtered responses at two successive time instants, at each time point.
- Special care is taken to tune the monitoring ultrasound waves in such a way (e.g. by adjusting its frequency and/or amplitude) as to generate sub- and ultraharmonics and to minimize rupture or destruction of the encapsulated gas-filled microparticles.
- the suspensions of encapsulated or stabilised gas bubbles useful in the present invention may be divided into three categories: stabilized microbubbles; microballoons (also called microcapsules); and microparticles. Free-gas bubbles are not included in these categories since, due to their rapid dissolution in the surrounding liquid; they are not stable enough to reliably deliver gas bubbles to the area of interest. Interest has accordingly been shown in methods of stabilising gas bubbles commonly used for echography and other ultrasonic studies, for example using emulsifiers, oils, thickeners or sugars, or by entrapping or encapsulating the gas or a precursor thereof in a variety of systems.
- the encapsulated or stabilized gas bubbles are microbubbles bounded by a very thin envelope involving the surfactant bound at the gas to liquid interface, microballoons (microcapsules or gas-filled liposomes) bounded by a material envelope made of organic polymers or biodegradable water insoluble and at room temperature solid lipids or microparticles having gas contained therein or otherwise associated therewith (for example being adsorbed on the surface thereof and/or contained within voids, cavities or pores therein) .
- the first category belonging to the class of microbubbles, specifically designates gas bubbles in suspension in a liquid preferably also containing surfactants or tensides to control the surface properties and the stability of the bubbles.
- the microbubble suspension comprises a surfactant or a tenside, such as, for example, a polyoxyethylene- polyoxypropylene block copolymer surfactant such as Pluronic® or a polymer surfactant like that disclosed in US 5,919,434.
- a surfactant or a tenside such as, for example, a polyoxyethylene- polyoxypropylene block copolymer surfactant such as Pluronic® or a polymer surfactant like that disclosed in US 5,919,434.
- a surfactant or a tenside such as, for example, a polyoxyethylene- polyoxypropylene block copolymer surfactant such as Pluronic® or a polymer surfactant like that disclosed in US 5,919,434.
- amphipathic compounds capable of forming stable films in the presence of water (or an aqueous carrier) and gas are used as surfactants in the stabilized microbubbles useful in the invention.
- Such compounds may include, for example a film
- the lipids, synthetic or naturally-occurring generally amphipathic and biocompatible, usable for preparing the gas-containing agents used in the present invention include, for example, fatty acids; lysolipids; phospholipids such as: phosphatidylcholine (PC) with both saturated and unsaturated lipids; including phosphatidylcholine such as dioleylphosphatidylcholine; dimyristoylphosphatidylcholine (DMPC) , dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine (DLPC); dipalmitoylphosphatidylcholine (DPPC); disteraoylphosphatidylcholine (DSPC); and diarachidonylphospha- tidylcholine (DAPC); phosphatidylethanolamines (PE), such as dioleylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine (DPPE) and diste
- GM1 and GM2 glucolipids; sulfatides; glycosphingolipids; phosphatidic acids as dipalmitoylphosphatidic acid (DPPA) and distearoylphosphatidic acid (DSPA); fatty acids such as: palmitic acid; stearic acid; arachidonic acid; oleic acid; lipids bearing polymers, such as chitin, hyaluronic acid, polyvinylpirrolidone or polyethylene glycol (PEG), also referred as "pegylated lipids", with preferred lipids bearing polymers including DPPE-PEG (DPPE-PEG), which refers to the lipid DPPE having a PEG polymer attached thereto, including, for example, DPPE-PEG2000, which refers to DPPE having attached thereto a PEG polymer having a mean average molecular weight of about 2000; lipids bearing sulfonated mono- di-, oligo- or polysaccharides
- the lipid is a film forming phospholipid and more preferably the film forming phospholipid material may be selected from saturated phospholipids or synthetic non-saturated phospholipids or a mixture thereof.
- suitable phospholipids are saturated synthetic lecithins, such as, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine or diarachidoylphosphatidylcholine or unsaturated synthetic lecithins, such as dioleylphosphatidyl choline or dilinoleylphosphatidylcholine or mixed chains phosphatidylcholine s such as for instance monooleyl- monopalmitoylphosphatidylcholine, with saturated phospholipids being preferred.
- the saturated phospholipid may be selected from saturated phosphatidic acid, saturated phosphatidylcholine, saturated phosphatidyl-ethanolamine, saturated phosphatidylserine, saturated phosphatidylglycerol, saturated
- saturated phospholipids selected in the following group: dimyristoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine , distearoyl- phosphatidylethanolamine or diarachidoylphosphatidylethanolamine;
- Additives like cholesterol and other substances can optionally be added to one or more of the foregoing lipids in proportions ranging from zero to 50% by weight.
- Such additives may include other non- phospholipid surfactants that can be used in admixture with the film forming surfactants and most of which are known. For instance
- the amount of these non- film- forming surfactants is usually up to 50% by weight of the total amount of surfactants but preferably between 0 and 30%.
- This category includes aqueous suspensions in which the gas bubbles are bounded at the gas/ liquid interface by a very thin layer of
- aqueous microbubble suspensions usable in the present invention are disclosed in, for example, EP 474833 (US 5,271,928), US 5,380,519, US 5,531,980, US 5,567,414, US 5,643,553, US 5,658,551, US 5,911,972, incorporated herein by reference in their entirety.
- the suspensions contain film forming surfactants in laminar and/ or lamellar form and, optionally, hydrophilic stabilisers. These microbubbles are stabilised by one or more mono-molecular layer(s) of amphipathic compounds i.e. compounds with hydrophilic and hydrophobic moieties.
- Preferred suspensions contain phospholipids as film forming surfactants and, optionally, hydrophilic stabilizers.
- the total concentration of phospholipids may range from 0.01% to 20% and preferably comprised between 0.01-10% (w/w) of the total lipid concentration and even most preferably between 0.1-1% (w/w).
- the concentration of microbubbles may range from 10 ⁇ to 1010 bubbles/ mL, with a preferred concentration of is between 10*3 and
- Preferred phospholipid monolayer stabilized microbubbles are also disclosed in for example, US 5,445,813; US 5,597,549; US 5,686,060 (Schneider et al), US 5,413,774; US 5,578,292 (Schneider et al), US 5,556,610; US 5,846,518 (Yan et al) and US 5,827,504 (Yan et al), incorporated herein by reference in their entirety.
- microbubble suspensions useful in the invention include those disclosed in, for example, US 5,798,091 (Trevino et al) and WO 97/29783 (Nycomed designating the US, also EP 881 915), incorporated herein by reference in their entirety.
- US 5,798,091 discloses what is stated to be a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant.
- the first surfactant is a hydrophobic phospholipid or mixture of phospholipids having at least one acyl chain, which comprises at least 10 carbon atoms, which is at least about 5% w/w of the total surfactant.
- the second surfactant is may or may not also be a phospholipid or mixture of phospholipids, but which is more hydrophilic than the phospholipid or combination of phospholipid provided as the first surfactant.
- Preferred second surfactants may be selected from the group consisting of phospholipids, phosphocholines, lysophospholipids, nonionic surfactants, neutral or anionic surfactants, fluorinated surfactants, which can be neutral or anionic, and combinations of such emulsifying or foaming agents.
- surfactants which are useful as the second surfactant include block copolymers of polyoxypropylene and polyoxyethylene (an example of such class of compounds is Pluronic, such as Pluronic F-68), sugar esters, fatty alcohols, aliphatic amine oxides, hyaluronic acid aliphatic esters, hyaluronic acid aliphatic ester salts, dodecyl poly(ethyleneoxy)ethanol, nonylphenoxy poly(ethyleneoxy) ethanol, derivatized starches, hydroxy ethyl starch fatty acid esters, salts of fatty acids, commercial food vegetable starches, dextran fatty acid esters, sorbitol fatty acid esters, gelatin, serum albumins, and combinations thereof.
- Pluronic such as Pluronic F-68
- sugar esters include fatty alcohols, aliphatic amine oxides, hyaluronic acid aliphatic esters, hyaluronic acid aliphatic ester salts, do
- a second surfactant are polyoxyethylene fatty acids esters, such as polyoxyethylene stearates, polyoxyethylene fatty alcohol ethers, polyoxyethylated sorbitan fatty acid esters, glycerol polyethylene glycol oxystearate, glycerol polyethylene glycol ricinoleate, ethoxylated soybean sterols, ethoxylated castor oils, and the hydrogenated derivatives thereof.
- nonionic alkylglucosides such as Tweens ®, Spans ® and Brijs ® may also be used as the second surfactant.
- a contrast agent for use in diagnostic studies comprising a suspension in an injectable aqueous carrier liquid of gas microbubbles stabilised by phospholipid- containing amphiphilic material characterised in that said amphiphilic material consists essentially of phospholipid predominantly comprising molecules with net charges.
- At least 75%, preferably substantially all of the phospholipid material in the contrast agents consists of molecules bearing a net overall charge under conditions of preparation and/ or use, which charge may be positive or, more preferably, negative.
- Representative positively charged phospholipids include esters of phosphatidic acids such as dipalmitoylphosphatidic acid or distearoylphosphatidic acid with aminoalcohols such as hydroxyethylenediamine.
- Examples of negatively charged phospholipids include naturally occurring (e.g. soya bean or egg yolk derived), semisynthetic (e.g. partially or fully hydrogenated) and synthetic phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins.
- the fatty acyl groups of such phospholipids will typically each contain about 14-22 carbon atoms, for example as in palmitoyl and stearoyl groups.
- Lyso forms of such charged phospholipids are also useful, the term "lyso" denoting phospholipids containing only one fatty acyl group, this preferably being ester-linked to the lposition carbon atom of the glyceryl moiety. Such lyso forms of charged phospholipids may advantageously be used in admixture with charged phospholipids containing two fatty acyl groups.
- the preparation of a preferred gas-filled microbubble suspension useful in the invention can be done according to, for example, the methods described in the following patents: EP 554213; US 5,413,774; US 5,578,292; EP 744962; EP 682530; US 5,556,610; EP 474833; US 5,271,928; US 5,380,519; US 5,531,980; US 5,567,414; EP 619743; US 5,445,813; US 5,597,549, incorporated by reference herein in their entirety.
- microbubbles used in the present invention may be produced with a very narrow size distribution for the microbubble dispersion within the range preferred for echography, thereby greatly enhancing their effective echogenicity as well as their safety in vivo, and rendering the microbubbles of particular advantage in such application.
- the second category includes contrast agents with a solid material envelope formed of natural or synthetic polymers.
- the gas filled bodies are referred to as microballoons.
- microballoon or “microcapsule” designates gas-filled bodies with a material boundary or envelope, i.e. a polymer membrane wall.
- Gas- filled liposomes according to, for example, US 5,580,575 (Unger) also belong to this category and are incorporated herein by reference.
- Microballoons which may be particularly useful in the present invention, include pressure resistant microballoons bounded by a soft and elastic membrane, which can temporarily deform under variations of pressure and are endowed with enhanced echogenicity and are biodegradable.
- the polymer which constitutes the envelope or bounding membrane of the injectable microballoons can be selected from most hydrophilic, biodegradable physiologically compatible polymers.
- Such polymers include polysaccharides of low water solubility, polylactides and polyglycolides and their copolymers, copolymers of lactides and lactones such as e-caprolactone, y - valerolactone and polypeptides.
- Other suitable polymers include poly-
- biodegradable polymers can be found in R. Langer et al., Macromol. Chem. Phys. C23 (1983), 61-126, incorporated herein by reference in its entirety.
- Polyamino-acids such as polyglutamic and polyaspartic acids can also be used as well as their derivatives, i.e. partial esters with lower alcohols or glycols.
- One useful example of such polymers is poly-(t.buryl-glutamate).
- Copolymers with other amino-acids such as methionine, leucine, valine, proline, glycine, alamine, etc. are also possible.
- Biodegradable water insoluble and at room temperature solid lipids selected from a mono-, di- or tri- glycerides, fatty acids, sterols, waxes and the mixtures thereof may also be used for the manufacture of microballoons according to the invention (see WO 96/ 15815 incorporated herein by reference in its entirety).
- Non-biodegradable polymers for making microballoons can be selected from most water-insoluble, physiologically acceptable, bioresistant polymers including polyolefins (polystyrene), acrylic resins (polyacrylates, polyacrylonitrile), polyesters (polycarbonate), polyurethanes, polyurea and their copolymers.
- ABS acryl-butadiene- styrene is a preferred copolymer.
- Additives can be incorporated into the polymer wall of the microballoons to modify the physical properties such as dispersibility, elasticity and water permeability.
- the useful additives one may cite compounds which can "hydrophobize" the microballoons membrane in order to decrease water permeability, such as fats, waxes and high molecular-weight hydrocarbons.
- Additives, which improve dispersibility of the microballoons in the injectable liquid carrier are amphipatic compounds like the phospholipids; they also increase water permeability and rate of biodegradability.
- the quantity of additives to be incorporated in the polymer forming the membrane of the present microballoons is extremely variable and depends on the needs. In some cases no additive is used at all, in other cases amounts of additives, which may reach about 20% by weight of the polymer, are possible.
- the third category of stabilized or encapsulated gas bubbles are microparticles, suspensions of porous particles of polymers or other solids, which carry gas microbubbles, entrapped within the pores of the microparticles.
- These systems which include aggregates of microparticles, have gas contained therein or otherwise associated therewith (for example being adsorbed on the surface thereof and/ or contained within voids, cavities or pores therein, e.g. as described in EP 0122 624, EP 0123 235, EP 0365 467, US 5,558,857, US 5,607,661, US 5,637,289, US 5,558,85, US 5, 137,928, WO 9521631 or WO 9313809, incorporated by reference herein in their entirety.
- the encapsulated or stabilised gas bubbles (stabilized microbubble, microballoon or microparticle suspensions) used in the present invention may conveniently be administered in a pharmaceutically acceptable aqueous liquid carrier.
- suitable liquid carriers are water, aqueous solutions such as saline (which may advantageously be balanced so that the final product for injection is not hypotonic), or solutions of one or more tonicity adjusting substances such as salts or sugars, sugar alcohols, glycols and other non-ionic polyol materials (e.g. glucose, sucrose, sorbitol, mannitol, glycerol, polyethylene glycols, propylene glycols and the like).
- all injectable compositions should also be as far as possible isotonic with blood.
- isotonic agents may also be added to the suspensions of the invention.
- the isotonic agents are physiological solutions commonly used in medicine and they comprise aqueous saline solution (0.9% NaCl), 2,6% glycerol solution, 5% dextrose solution, etc.
- excipients may if desired be present in the composition being dried or may be added on formulation for administration.
- excipients may for example include pH regulators, osmolality adjusters, viscosity enhancers, emulsifiers, bulking agents, etc. and may be used in conventional amounts.
- the encapsulated or stabilised gas bubbles are filled with a gas or a gas mixture comprising a physiologically acceptable gas selected from the group consisting of fluorinated gases, including sulfur hexafluoride, trifluoromethylsulfur pentafluoride, Freons® (e.g.
- organic compounds containing one or more carbon atoms and fluorine such as CF 4 , CBrF 3 , C 4 F 8 , CC1F 3 , CC1 2 F 2 , C 2 F 6 , C 2 C1F 5 , CBrClF 2 , CBr F 2; C 3 F 8 and C 4 F 10 and mixtures thereof), and perfluorocarbons; air; nitrogen; oxygen; carbon dioxide; hydrogen; nitrous oxide; inert gases such as helium, krypton, xenon, and argon; hyperpolarized gases; a low molecular weight hydrocarbon (e.g.
- halogenated low molecular weight hydrocarbon e.g. containing up to 7 carbon atoms
- halogenated gases advantageously are fluorine atoms.
- Biocompatible halogenated hydrocarbon gases may, for example, be selected from bromochlorodifluoromethane, chlorodifluorome thane, dichlorodifluorome thane, bromotrifluorome thane, chlorotrifluoromethane, chloropentafluoroethane, dichlorotetrafluoroethane and perfluorocarbons, e.g. perfiuoroalkanes such as perfluorome thane, perfluoroethane, perfluoropropanes, perfluorobutanes (e.g.
- perfluoro-n-butane optionally in admixture with other isomers such as perfluoro-isobutane), perfluoropentanes, perfluorohexanes and perfluoroheptanes, pefluorooctanes, perfluorononanes, perfluorodecan.es; perfluoroalkenes such as perfluoropropene, perfluorobutenes (e.g.
- perfluorobut-2ene and perfluorobutadiene
- perfluoroalkynes such as perfluorobut-2-yne
- perfluorocycloalkanes such as perfluorocyclobutane, perfluoromethylcyclobutane, perfluorodimethylcyclobutanes, perfluorotrimethylcyclobutanes, perfluorocyclopentane, perfluoromethylcyclopentane, perfluorodimethylcyclopentanes, perfluorocyclohexane, perfluorome thylcyclohexane and perfiuorocycloheptane.
- Other halogenated gases include fluorinated, e.g.
- the gas can be a mixture of the gases above defined. In particular the following combinations are particularly preferred: a mixture of gases
- the contrast agent may include a gas precursor (e.g. a compound or compound mixture which is partially in gaseous form (including vapour) at normal human body temperatures (37 °C) i.e. C5F12, C6F14, cyclohexane, cyclooctane, hexane, cyclopentane, etc.).
- a gas precursor e.g. a compound or compound mixture which is partially in gaseous form (including vapour) at normal human body temperatures (37 °C) i.e. C5F12, C6F14, cyclohexane, cyclooctane, hexane, cyclopentane, etc.
- gas precursors with boiling points between 20 and 80 °C.
- the gas precursor may be used alone or in combination with a gas or another gas precursor.
- FIG. 4 shows the sub- and ultraharmonic energy curves (top and bottom, respectively) as a function of time for an air bubble with a radius of 2.2 ⁇ m as obtained by computer simulation.
- the curves were calculated, as described in the specification, for different values of the surrounding liquid pressure.
- the liquid pressure is indicated by the overpressure, i.e. the pressure value over the atmospheric pressure of 760 mmHg.
- the values for the overpressure were 0, 50,
- Disappearance time, td mean response times for subharmonic, t sub, and ultraharmonic, t ul, as a function of the overpressure.
- Example 2 This example shows the sensitivity of the new method to measure clinical relevant pressure differences of 10 mmHg, for an air bubble with a radius of 2.2 ⁇ m as obtained by computer simulation.
- the results of this example are shown in table 2.
- the overpressures range from 80 to 120 mmHg in steps of 10 mmHg.
- the difference in disappearance time ranges from 1.2 to 1.4 ms per 10 mmHg of pressure change.
- the difference in mean response time for the subharmonic (column 3 in table 2) ranges from 1.7 to 2.7 ms.
- Disappearance time, td mean response times for subharmonic, t_sub, and ultraharmonic, tjul, as a function of the overpressure.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/474,134 US6962071B2 (en) | 2001-04-06 | 2002-04-05 | Method for improved measurement of local physical parameters in a fluid-filled cavity |
JP2002578814A JP3819845B2 (en) | 2001-04-06 | 2002-04-05 | Improved method for measuring local physical parameters in fluid filled cavities |
EP02722575A EP1387637B1 (en) | 2001-04-06 | 2002-04-05 | Apparatus for measuring local physical parameters in a fluid filled cavity |
AU2002253454A AU2002253454A1 (en) | 2001-04-06 | 2002-04-05 | Method for improved measurement of local physical parameters in afluid-filled cavity |
DE60223239T DE60223239T2 (en) | 2001-04-06 | 2002-04-05 | Device for measuring local physical parameters in a liquid-filled cavity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28179401P | 2001-04-06 | 2001-04-06 | |
US60/281,794 | 2001-04-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002080774A2 true WO2002080774A2 (en) | 2002-10-17 |
WO2002080774A3 WO2002080774A3 (en) | 2003-02-27 |
Family
ID=23078815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/001229 WO2002080774A2 (en) | 2001-04-06 | 2002-04-05 | Method for improved measurement of local physical parameters in afluid-filled cavity |
Country Status (7)
Country | Link |
---|---|
US (1) | US6962071B2 (en) |
EP (1) | EP1387637B1 (en) |
JP (1) | JP3819845B2 (en) |
AT (1) | ATE376803T1 (en) |
AU (1) | AU2002253454A1 (en) |
DE (1) | DE60223239T2 (en) |
WO (1) | WO2002080774A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1694689A (en) * | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | Sustained release pharmaceutical formulation for inhalation |
US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
US6962006B2 (en) * | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
CA2533887A1 (en) * | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Injectable, oral, or topical sustained release pharmaceutical formulations |
US20050273010A1 (en) * | 2004-06-02 | 2005-12-08 | Shi William T | Method and system for ultrasound contrast-imaging |
US7837626B2 (en) * | 2005-08-05 | 2010-11-23 | Siemens Medical Solutions Usa, Inc. | Contrast agent manipulation with medical ultrasound imaging |
EP1780651A1 (en) * | 2005-10-25 | 2007-05-02 | Bracco Imaging, S.P.A. | Method and system for automatic processing and evaluation of images, particularly diagnostic images |
US10130342B2 (en) | 2007-12-28 | 2018-11-20 | Bracco Suisse Sa | Initialization of fitting parameters for perfusion assessment based on bolus administration |
JP5341995B2 (en) * | 2009-06-18 | 2013-11-13 | 株式会社日立メディコ | Ultrasonic imaging apparatus and method of operating ultrasonic imaging apparatus |
CA2839890A1 (en) * | 2011-06-22 | 2012-12-27 | 1St Detect Corporation | Reduced pressure liquid sampling |
DE102013006943B4 (en) * | 2013-04-23 | 2021-03-18 | Khs Gmbh | Method and device for leak testing large-volume containers |
CN106163412B (en) * | 2014-04-07 | 2019-10-11 | 博莱科瑞士股份有限公司 | Estimation in situ is carried out to sound level using non-Analysis of Fundamental Frequencies |
KR20180091025A (en) | 2015-12-10 | 2018-08-14 | 브라코 스위스 에스.에이. | Detection of Fixed Contrast Agent by Dynamic Thresholding |
JP7104709B2 (en) * | 2016-10-11 | 2022-07-21 | トーマス・ジェファーソン・ユニバーシティ | Non-invasive method for pressure measurement |
CN108459357B (en) * | 2018-03-01 | 2019-07-05 | 中国石油大学(华东) | The evaluation method of stratum undercompaction and fluid expansion superpressure |
US20210259666A1 (en) * | 2020-02-21 | 2021-08-26 | Alexander Brenner | System and method for non-invasive real time assessment of cardiovascular blood pressure |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032378A1 (en) * | 1997-01-22 | 1998-07-30 | Quadrant Healthcare (Uk) Limited | Ultrasound contrast imaging |
WO1999047045A1 (en) * | 1998-03-20 | 1999-09-23 | Thomas Jefferson University | Microbubble-based ultrasonic contrast agents for pressure measurements |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4180646A (en) * | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4131648A (en) * | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
DE2946662A1 (en) | 1979-11-19 | 1981-05-27 | Siemens AG, 1000 Berlin und 8000 München | Blood pressure measuring appts. - uses ultrasonic waves with volume variation of injected gas bubbles indicated from size of reflected waves |
JPS5826238A (en) * | 1981-08-08 | 1983-02-16 | Fujitsu Ltd | Pressure measurement system by ultrasonic wave |
US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
JPS59164035A (en) * | 1983-03-09 | 1984-09-17 | 三菱電機株式会社 | Internal pressure measuring apparatus of living body tissue |
DE3313947A1 (en) | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS |
DE3313946A1 (en) | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS |
DE3834705A1 (en) | 1988-10-07 | 1990-04-12 | Schering Ag | ULTRASONIC CONTRASTING AGENTS FROM GAS BUBBLES AND MICROPARTICLES CONTAINING FATTY ACID |
US4900540A (en) * | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
JPS60501759A (en) * | 1983-07-01 | 1985-10-17 | バテル メモリアル インステイチユ−ト | Biodegradable polypeptides and their use for slow release of drugs |
EP0179023B1 (en) * | 1984-10-19 | 1991-01-23 | Battelle Memorial Institute | With micro-organisms degradable polypeptide, and its use for the progressive release of medicaments |
CH667874A5 (en) * | 1985-12-19 | 1988-11-15 | Battelle Memorial Institute | BIODEGRADABLE SYNTHETIC POLYPEPTIDE AND ITS USE FOR THE PREPARATION OF MEDICAMENTS. |
DE3637926C1 (en) | 1986-11-05 | 1987-11-26 | Schering Ag | Ultrasonic manometry in a liquid using microbubbles |
US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
IE61591B1 (en) | 1987-12-29 | 1994-11-16 | Molecular Biosystems Inc | Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5230882A (en) * | 1989-12-22 | 1993-07-27 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5578292A (en) * | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
US5556610A (en) * | 1992-01-24 | 1996-09-17 | Bracco Research S.A. | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
US5445813A (en) | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
IN172208B (en) | 1990-04-02 | 1993-05-01 | Sint Sa | |
US5137928A (en) * | 1990-04-26 | 1992-08-11 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
GB9106673D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
WO1992021382A1 (en) * | 1991-06-03 | 1992-12-10 | Holmes, Michael, John | Improvements in or relating to contrast agents |
JPH06510758A (en) * | 1991-07-05 | 1994-12-01 | ニユコメド・イメージング・アクシエセルカペト | Improvements in or relating to contrast agents |
GB9200387D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
GB9200391D0 (en) | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
IL104084A (en) | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them |
KR100218642B1 (en) | 1993-07-02 | 1999-09-01 | 스티븐 로손 | Method of making microspheres encapsulated from the temperature-denaturated protein |
US5798091A (en) * | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
GB9318288D0 (en) * | 1993-09-03 | 1993-10-20 | Nycomed Imaging As | Improvements in or relating to contrast agents |
PT682530E (en) | 1993-12-15 | 2003-06-30 | Bracco Research Sa | UTEIS GAS MIXTURES AS CONTRAST MEANS FOR ULTRASSONS |
GB9402867D0 (en) | 1994-02-15 | 1994-04-06 | Nycomed Imaging As | Improvements in or relating to contrast agents |
GB9417941D0 (en) * | 1994-09-06 | 1994-10-26 | Nycomed Imaging As | Improvements in or relating to contrast agents |
US6333021B1 (en) | 1994-11-22 | 2001-12-25 | Bracco Research S.A. | Microcapsules, method of making and their use |
IL116328A (en) | 1994-12-16 | 1999-09-22 | Bracco Research Sa | Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging |
JP3697292B2 (en) * | 1995-05-17 | 2005-09-21 | 株式会社東芝 | Ultrasonic diagnostic equipment |
SK284200B6 (en) | 1996-02-19 | 2004-10-05 | Amersham Health As | Improvements in or relating to contrast agents |
US5749364A (en) * | 1996-06-21 | 1998-05-12 | Acuson Corporation | Method and apparatus for mapping pressure and tissue properties |
JPH11244284A (en) * | 1998-03-05 | 1999-09-14 | Ge Yokogawa Medical Systems Ltd | Ultrasonographic method and equipment |
GB9808582D0 (en) * | 1998-04-22 | 1998-06-24 | Nycomed Imaging As | Improvements in or relating to contrast agents |
US6758090B2 (en) * | 1998-06-15 | 2004-07-06 | Schlumberger Technology Corporation | Method and apparatus for the detection of bubble point pressure |
JP2002527410A (en) * | 1998-10-12 | 2002-08-27 | マリンクロッド・インコーポレイテッド | New ultrasonic contrast agent |
US6224554B1 (en) * | 1999-03-31 | 2001-05-01 | Point Biomedical Corporation | Method to measure ambient fluid pressure |
-
2002
- 2002-04-05 US US10/474,134 patent/US6962071B2/en not_active Expired - Fee Related
- 2002-04-05 JP JP2002578814A patent/JP3819845B2/en not_active Expired - Fee Related
- 2002-04-05 AU AU2002253454A patent/AU2002253454A1/en not_active Abandoned
- 2002-04-05 WO PCT/IB2002/001229 patent/WO2002080774A2/en active IP Right Grant
- 2002-04-05 EP EP02722575A patent/EP1387637B1/en not_active Expired - Lifetime
- 2002-04-05 DE DE60223239T patent/DE60223239T2/en not_active Expired - Lifetime
- 2002-04-05 AT AT02722575T patent/ATE376803T1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032378A1 (en) * | 1997-01-22 | 1998-07-30 | Quadrant Healthcare (Uk) Limited | Ultrasound contrast imaging |
WO1999047045A1 (en) * | 1998-03-20 | 1999-09-23 | Thomas Jefferson University | Microbubble-based ultrasonic contrast agents for pressure measurements |
Also Published As
Publication number | Publication date |
---|---|
EP1387637A2 (en) | 2004-02-11 |
JP2004529697A (en) | 2004-09-30 |
AU2002253454A1 (en) | 2002-10-21 |
ATE376803T1 (en) | 2007-11-15 |
EP1387637B1 (en) | 2007-10-31 |
WO2002080774A3 (en) | 2003-02-27 |
DE60223239T2 (en) | 2008-08-14 |
US20040129082A1 (en) | 2004-07-08 |
US6962071B2 (en) | 2005-11-08 |
DE60223239D1 (en) | 2007-12-13 |
JP3819845B2 (en) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6962071B2 (en) | Method for improved measurement of local physical parameters in a fluid-filled cavity | |
US10076580B2 (en) | Gas-filled microvesicles composition for contrast imaging | |
US6592846B1 (en) | Long-lasting aqueous dispersions or suspensions of pressure resistant gas-filled microvesicles and methods for thereof preparation thereof | |
US6881397B2 (en) | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof | |
EP1701745B1 (en) | Gas-filled microvesicle assembly for contrast imaging | |
CA2545362C (en) | Assembly of gas-filled microvesicle with active component for contrast imaging | |
WO1998047533A1 (en) | Ultrasound imaging of tissue perfusion by pulse energy disruption of contrast agent | |
US20050025710A1 (en) | Reconstitutable formulation and aqueous suspension of gas-filled microvesicles for diagnostic imaging | |
US20010021371A1 (en) | Improvements in or relating to cardiac imaging | |
US20050165311A1 (en) | Detection of endothelial dysfunction by ultrasonic imaging | |
US20060034771A1 (en) | Ultrasound contrast agents and methods of making and using them | |
US20010008626A1 (en) | Ultrasound contrast agents and methods of making and using them | |
USRE39146E1 (en) | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof | |
US20030064030A1 (en) | Ultrasound contrast agents and methods of making and using them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10474134 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002578814 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002722575 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002722575 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002722575 Country of ref document: EP |